Kim Ji Eun, Lee Young Ju, Ryu Sung Ha, Park Ji Won, Kang Mi Ju, Choi Hyeon Jun, Bae Su Ji, Choi Yusang, Kang Hyun Gu, Kim Kyu-Bong, Kim Suhkmann, Lim Yong, Hwang Dae Youn
1Department of Biomaterials Science, College of Natural Resources & Life Science / Industry Convergence Research Institute, Pusan National University, 50 Cheonghak-ri, Samnangjin-eup Miryang-si, Gyeongsangnam-do 627-706 South Korea.
Analysis Research Team, R&D Center, GL Pharm Tech Corp, Gyeonggi-do, 13202 Republic of Korea.
Lab Anim Res. 2019 Jul 24;35:9. doi: 10.1186/s42826-019-0009-x. eCollection 2019.
Red (RLP) is a known herbal medicine used in the treatment of some chronic diseases including constipation, neurodegenerative disorders, diabetes and obesity. To determine and characterize putative biomarkers that predict the laxative effects induced by RLP treatment, alteration of endogenous metabolites was measured in the serum of loperamide (Lop)-induced constipation rats after administration of RLP extract (EtRLP) using H nuclear magnetic resonance (H NMR) spectral data. The urine volume and amounts, and weights and water contents of stools were significantly recovered in the Lop + EtRLP treated group as compared to the No group, whereas body weight and food intake maintained constant levels. Also, significant recoveries in the thickness of mucosa and muscle were detected in the colon of the Lop + EtRLP treated group. Furthermore, pattern recognition showed absolutely different clustering of the serum analysis parameters when comparing the Lop treated group and Lop + EtRLP treated group. Of the 33 endogenous metabolites, 7 amino acids (alanine, arginine, glutamate, glutamine, glycine, threonine and valine) and 8 endogenous metabolites (betaine, creatine, glucose, taurine, ethanol, lactate, glycerol and succinate) were dramatically increased in the Lop + EtRLP treated SD rats. These results provide the first evidence pertaining to metabolic changes in the constipation rats treated with Lop + EtRLP. Additionally, these findings correlate with changes observed in 15 metabolites during the laxative effects of EtRLP.
红曲(RLP)是一种已知的草药,用于治疗一些慢性疾病,包括便秘、神经退行性疾病、糖尿病和肥胖症。为了确定并表征预测RLP治疗诱导的通便作用的潜在生物标志物,使用氢核磁共振(¹H NMR)光谱数据,在给予洛哌丁胺(Lop)诱导的便秘大鼠血清中,测定了给予RLP提取物(EtRLP)后内源性代谢物的变化。与未治疗组相比,Lop + EtRLP治疗组的尿量和粪便量、重量及含水量均有显著恢复,而体重和食物摄入量保持恒定水平。此外,在Lop + EtRLP治疗组的结肠中,检测到黏膜和肌肉厚度有显著恢复。此外,模式识别显示,比较Lop治疗组和Lop + EtRLP治疗组时,血清分析参数的聚类完全不同。在33种内源性代谢物中,Lop + EtRLP治疗的SD大鼠中有7种氨基酸(丙氨酸、精氨酸、谷氨酸、谷氨酰胺、甘氨酸、苏氨酸和缬氨酸)和8种内源性代谢物(甜菜碱、肌酸、葡萄糖、牛磺酸、乙醇、乳酸、甘油和琥珀酸)显著增加。这些结果提供了关于Lop + EtRLP治疗便秘大鼠代谢变化的首个证据。此外,这些发现与EtRLP通便作用期间15种代谢物中观察到的变化相关。